Genmab (Otc) (GMAB)
NASDAQ:GMAB
Want to see GMAB full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.34Last Year’s EPS
0.54Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum, meaningful top-line growth, improving profitability and a catalyst-rich 2026 driven by multiple late-stage readouts (EPKINLY, Rina-S, petosemtamab). Management highlighted disciplined but sizeable investments to support launches and pipeline advancement and reported faster-than-expected enrollment on key trials. Key risks discussed include near-term tax-rate volatility tied to Merus integration, substantial planned operating spend, a hypercompetitive landscape for Rina-S, and dependency on several binary clinical readouts. Overall, the positives from robust revenue/receipt growth, operating profit expansion, completed pivotal enrollment and multiple upcoming catalysts materially outweigh the outlined uncertainties.Company Guidance
Total Revenue Growth
Q1 2026 total revenue grew 25% year-over-year, reflecting diversified revenue from royalties (DARZALEX, Kesimpta) and increasing product sales from Genmab's proprietary medicines.
Proprietary Portfolio Sales Momentum
Proprietary product sales totaled $176 million in Q1 (up 43% year-over-year), driven by strong uptake of EPKINLY and Tivdak across new and established markets.
EPKINLY Commercial Performance and Label Update
EPKINLY sales reached $137 million in the quarter (up 52% year-over-year). Key commercial and regulatory wins include fixed-duration approval with R2 in second-line FL, approvals in >65 countries (many dual indications), and an FDA label revision removing a required 24-hour hospitalization recommendation for first full dose in third-line DLBCL—expected to broaden outpatient/community use.
Tivdak Growth and Geographic Expansion
Tivdak sales were $39 million in Q1 (up 18% year-over-year). Continued leadership in the U.S. recurrent/metastatic cervical cancer market and expansion efforts in Japan, Europe (direct commercialization in Japan and Europe), and the U.K. (private prescribing launch and NICE/SMC engagement) support further growth.
Profitability While Investing in Growth
Genmab grew operating profit by 23% in Q1 despite stepping up investments in late-stage development and launch readiness. 2026 guidance remains on track with a midpoint revenue growth expectation of ~14% and planned operating expenses of ~$2.7–2.9 billion.
Rina-S Development Acceleration and Milestones
Rina-S program advanced materially: RAINFOL-02 (Phase III in second-line plus platinum-resistant ovarian cancer) completed enrollment ahead of expectations, bringing pivotal Phase III data into 2026; two new Phase III trials (including a chemo-replacement in platinum-sensitive ovarian cancer and the first frontline endometrial trial) are anticipated to start in coming months. Two datasets for Rina-S in platinum-resistant ovarian cancer are expected in H2 2026, supporting potential 2027 launches.
Petosemtamab Progress & Merus Integration
Petosemtamab development remains on track with one or more readouts expected this year; Merus integration is underway and being pursued to capture the full value of petosemtamab, while acquisition-related expenses/amortization are excluded from the presented results (reconciliation in appendix).
Clinical Execution and Faster-than-Expected Enrollment
Several trials (including RAINFOL-02 and multiple EPKINLY trials) have accrued faster than originally projected, accelerating expected readouts and creating a catalyst-rich 2026 with potential supporting launches in 2027.
GMAB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GMAB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $27.89 | $27.06 | -2.98% |
Feb 17, 2026 | $30.03 | $30.00 | -0.10% |
Nov 10, 2025 | $28.66 | $29.06 | +1.40% |
Aug 07, 2025 | $21.51 | $22.69 | +5.49% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Genmab (Otc) (GMAB) report earnings?
Genmab (Otc) (GMAB) is schdueled to report earning on Aug 06, 2026, Before Open (Confirmed).
What is Genmab (Otc) (GMAB) earnings time?
Genmab (Otc) (GMAB) earnings time is at Aug 06, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GMAB EPS forecast?
GMAB EPS forecast for the fiscal quarter 2026 (Q2) is 0.34.